| scholarly article | Q13442814 |
| P50 | author | Mei-Ling Ting Lee | Q42116320 |
| Ken M. Riedl | Q42712187 | ||
| P2093 | author name string | Steven K Clinton | |
| Gregory B Lesinski | |||
| Steven J Schwartz | |||
| Gregory S Young | |||
| Raul Cruz-Cano | |||
| Yael Vodovotz | |||
| Elizabeth M Grainger | |||
| Jennifer H Ahn-Jarvis | |||
| P2860 | cites work | Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora | Q28143631 |
| Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents | Q28254959 | ||
| Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako) | Q28285358 | ||
| Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy | Q33333660 | ||
| Dietary intake and bioavailability of polyphenols | Q33985768 | ||
| Urine accurately reflects circulating isoflavonoids and ascertains compliance during soy intervention | Q34179479 | ||
| High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. | Q34475991 | ||
| Apparent bioavailability of isoflavones after intake of liquid and solid soya foods | Q35629640 | ||
| Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. | Q36249153 | ||
| Impact of food matrix on isoflavone metabolism and cardiovascular biomarkers in adults with hypercholesterolemia | Q36284893 | ||
| Estimated Asian adult soy protein and isoflavone intakes | Q36590662 | ||
| Association between plasma cholesterol and prostate cancer in the PSA era. | Q36877126 | ||
| The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model. | Q36924955 | ||
| Soy isoflavone genistein in prevention and treatment of prostate cancer | Q36965664 | ||
| Design and selection of soy breads used for evaluating isoflavone bioavailability in clinical trials. | Q37244017 | ||
| Perspectives in mammalian IGFBP-3 biology: local vs. systemic action | Q37412844 | ||
| Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial | Q37577822 | ||
| Factors that modify radiation-induced carcinogenesis | Q37612760 | ||
| Insulin-like growth factor-I and prostate cancer: a meta-analysis | Q38281197 | ||
| Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones | Q40201709 | ||
| Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro | Q40337227 | ||
| Treatment with antibiotics reduces plasma equol concentration in cynomolgus monkeys (Macaca fascicularis). | Q40577199 | ||
| Polyphenols, Inflammatory Response, and Cancer Prevention: Chlorination of Isoflavones by Human Neutrophils | Q40618186 | ||
| Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). | Q43739435 | ||
| Anaerobic C-ring cleavage of genistein and daidzein by Eubacterium ramulus. | Q43963290 | ||
| Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells | Q44060322 | ||
| Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats | Q44378229 | ||
| Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. | Q44576278 | ||
| Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton | Q44708128 | ||
| Stability and bioaccessibility of isoflavones from soy bread during in vitro digestion | Q44713753 | ||
| Soy isoflavones in the treatment of prostate cancer | Q44846552 | ||
| Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes | Q45075689 | ||
| Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. | Q46023216 | ||
| The role of diet in the metabolism of daidzein by human faecal microbiota sampled from Italian volunteers. | Q46205555 | ||
| A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen | Q46621115 | ||
| Absorption of isoflavones in humans: effects of food matrix and processing | Q46657968 | ||
| The metabolic fate of daidzein | Q47655272 | ||
| Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. | Q53332234 | ||
| Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. | Q53924951 | ||
| In vitro bioassays of non-steroidal phytoestrogens | Q70731013 | ||
| Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule | Q73018621 | ||
| Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans | Q73924402 | ||
| Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability | Q74529751 | ||
| Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women | Q74764294 | ||
| Antioxidant activities of isoflavones and their biological metabolites in a liposomal system | Q77094970 | ||
| Bioavailability of isoflavones after ingestion of soy beverages in healthy adults | Q80142226 | ||
| The apparent absorptions of isoflavone glucosides and aglucons are similar in women and are increased by rapid gut transit time and low fecal isoflavone degradation | Q80822897 | ||
| Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods | Q81645253 | ||
| Higher bioavailability of isoflavones after a single ingestion of aglycone‐rich fermented soybeans compared with glucoside‐rich non‐fermented soybeans in Japanese postmenopausal women | Q82590970 | ||
| P433 | issue | 11 | |
| P921 | main subject | bread | Q7802 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 1045-1054 | |
| P577 | publication date | 2015-08-14 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer | |
| P478 | volume | 8 |
| Q93370579 | A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer |
| Q36249153 | Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. |
| Q92410860 | Dietary Carcinogens and DNA Adducts in Prostate Cancer |
| Q38891659 | Food-based natural products for cancer management: Is the whole greater than the sum of the parts? |
| Q57109257 | Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations |
| Q47970799 | Pharmacokinetic Properties of Saffron and its Active Components. |
| Q64057097 | Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function |
| Q104459182 | Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis |
Search more.